| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydrogen Sulfide | 15 | 2023 | 38 | 4.990 |
Why?
|
| Iris | 20 | 2010 | 30 | 3.100 |
Why?
|
| Retina | 18 | 2018 | 255 | 3.000 |
Why?
|
| Ciliary Body | 14 | 2018 | 23 | 2.130 |
Why?
|
| Cattle | 36 | 2021 | 472 | 1.880 |
Why?
|
| Norepinephrine | 19 | 2015 | 107 | 1.750 |
Why?
|
| D-Aspartic Acid | 7 | 2018 | 9 | 1.500 |
Why?
|
| Hydrogen Peroxide | 12 | 2021 | 181 | 1.480 |
Why?
|
| Sympathetic Nervous System | 10 | 2015 | 74 | 1.350 |
Why?
|
| Cyclic AMP | 9 | 2012 | 125 | 1.310 |
Why?
|
| Eye | 6 | 2011 | 68 | 1.270 |
Why?
|
| Ciliary Arteries | 3 | 2018 | 6 | 1.180 |
Why?
|
| Intraocular Pressure | 6 | 2018 | 121 | 1.130 |
Why?
|
| Ophthalmic Solutions | 4 | 2018 | 18 | 1.120 |
Why?
|
| Isoprostanes | 6 | 2014 | 14 | 1.100 |
Why?
|
| Cysteine | 8 | 2019 | 88 | 1.080 |
Why?
|
| Animals | 70 | 2023 | 14307 | 1.080 |
Why?
|
| Aspartic Acid | 6 | 2018 | 46 | 1.060 |
Why?
|
| Synaptic Transmission | 9 | 2015 | 141 | 0.990 |
Why?
|
| Muscle Contraction | 5 | 2018 | 63 | 0.960 |
Why?
|
| Neurotransmitter Agents | 4 | 2011 | 57 | 0.860 |
Why?
|
| Serotonin Antagonists | 5 | 2018 | 22 | 0.850 |
Why?
|
| Aqueous Humor | 2 | 2017 | 18 | 0.780 |
Why?
|
| Prostaglandins | 8 | 2015 | 25 | 0.740 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2018 | 984 | 0.730 |
Why?
|
| Organothiophosphorus Compounds | 4 | 2018 | 7 | 0.710 |
Why?
|
| Tritium | 10 | 2011 | 48 | 0.690 |
Why?
|
| Morpholines | 4 | 2018 | 65 | 0.680 |
Why?
|
| Peroxides | 4 | 2005 | 20 | 0.660 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2018 | 5 | 0.650 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2018 | 6 | 0.650 |
Why?
|
| Citrates | 7 | 2009 | 12 | 0.620 |
Why?
|
| Cyclooxygenase Inhibitors | 9 | 2012 | 28 | 0.620 |
Why?
|
| Glaucoma | 2 | 2017 | 87 | 0.620 |
Why?
|
| Cystathionine gamma-Lyase | 6 | 2015 | 12 | 0.610 |
Why?
|
| Phenylephrine | 2 | 2015 | 34 | 0.610 |
Why?
|
| Sulfides | 7 | 2023 | 58 | 0.610 |
Why?
|
| Eye Diseases | 3 | 2018 | 23 | 0.590 |
Why?
|
| Piperidines | 3 | 2015 | 76 | 0.580 |
Why?
|
| Dinoprost | 5 | 2008 | 22 | 0.580 |
Why?
|
| Dinoprostone | 7 | 2009 | 57 | 0.580 |
Why?
|
| Muscle, Smooth | 4 | 2010 | 51 | 0.570 |
Why?
|
| Muscle Relaxation | 4 | 2015 | 17 | 0.550 |
Why?
|
| Cystathionine beta-Synthase | 5 | 2015 | 12 | 0.530 |
Why?
|
| Pyrrolidines | 1 | 2015 | 26 | 0.520 |
Why?
|
| Organophosphorus Compounds | 1 | 2015 | 36 | 0.520 |
Why?
|
| Glycine | 4 | 2012 | 44 | 0.520 |
Why?
|
| Electric Stimulation | 15 | 2015 | 177 | 0.500 |
Why?
|
| Vasoconstrictor Agents | 4 | 2015 | 38 | 0.490 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 127 | 0.490 |
Why?
|
| Potassium Chloride | 5 | 2009 | 25 | 0.480 |
Why?
|
| Vasodilation | 1 | 2013 | 65 | 0.460 |
Why?
|
| Swine | 6 | 2023 | 182 | 0.430 |
Why?
|
| Flurbiprofen | 8 | 2009 | 10 | 0.430 |
Why?
|
| KATP Channels | 4 | 2015 | 11 | 0.420 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2012 | 30 | 0.420 |
Why?
|
| Oxidative Stress | 7 | 2021 | 874 | 0.410 |
Why?
|
| Calcium | 3 | 2018 | 445 | 0.400 |
Why?
|
| Cataract | 2 | 2021 | 26 | 0.380 |
Why?
|
| Catecholamines | 2 | 2018 | 43 | 0.370 |
Why?
|
| F2-Isoprostanes | 3 | 2011 | 20 | 0.360 |
Why?
|
| Rabbits | 12 | 2016 | 278 | 0.350 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 12 | 0.340 |
Why?
|
| Uterus | 4 | 1991 | 54 | 0.340 |
Why?
|
| Air Pollutants | 1 | 2009 | 90 | 0.340 |
Why?
|
| Glutamic Acid | 3 | 2009 | 115 | 0.320 |
Why?
|
| Histamine | 2 | 2006 | 17 | 0.310 |
Why?
|
| Catalase | 2 | 2000 | 106 | 0.310 |
Why?
|
| Calcium Channel Blockers | 3 | 2003 | 56 | 0.310 |
Why?
|
| Free Radicals | 2 | 2005 | 72 | 0.300 |
Why?
|
| Carbachol | 5 | 2010 | 18 | 0.300 |
Why?
|
| Aporphines | 2 | 2005 | 16 | 0.300 |
Why?
|
| Uvea | 2 | 2015 | 3 | 0.300 |
Why?
|
| Serotonin | 3 | 2002 | 114 | 0.290 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2000 | 33 | 0.280 |
Why?
|
| Ischemia | 1 | 2006 | 45 | 0.280 |
Why?
|
| Cannabinoids | 1 | 2006 | 54 | 0.270 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 32 | 0.260 |
Why?
|
| Excitatory Amino Acid Agonists | 2 | 2001 | 47 | 0.260 |
Why?
|
| Receptors, Prostaglandin | 4 | 2009 | 10 | 0.250 |
Why?
|
| Receptors, Serotonin | 4 | 2018 | 21 | 0.250 |
Why?
|
| Receptors, Thromboxane | 4 | 2008 | 4 | 0.250 |
Why?
|
| Arachidonic Acids | 1 | 2004 | 24 | 0.250 |
Why?
|
| Vitreous Body | 1 | 2003 | 11 | 0.240 |
Why?
|
| Alanine | 1 | 2003 | 28 | 0.240 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2001 | 11 | 0.240 |
Why?
|
| Lipid Peroxidation | 3 | 2004 | 131 | 0.240 |
Why?
|
| Rats | 13 | 2012 | 3261 | 0.230 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 1997 | 33 | 0.230 |
Why?
|
| Isometric Contraction | 2 | 2015 | 21 | 0.230 |
Why?
|
| Amino Acids | 1 | 2003 | 139 | 0.230 |
Why?
|
| Neurons | 1 | 2009 | 1130 | 0.220 |
Why?
|
| Glucose | 1 | 2003 | 217 | 0.210 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2001 | 21 | 0.210 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2001 | 92 | 0.200 |
Why?
|
| Receptors, Muscarinic | 3 | 2010 | 16 | 0.200 |
Why?
|
| Organ Culture Techniques | 3 | 2008 | 99 | 0.200 |
Why?
|
| Uterine Contraction | 3 | 1991 | 6 | 0.200 |
Why?
|
| Alkynes | 2 | 2012 | 49 | 0.190 |
Why?
|
| Hydrazines | 4 | 2009 | 21 | 0.180 |
Why?
|
| Drug Synergism | 4 | 2003 | 171 | 0.180 |
Why?
|
| Body Weight | 4 | 2007 | 404 | 0.180 |
Why?
|
| Nitric Oxide | 2 | 2015 | 287 | 0.180 |
Why?
|
| Fatty Acids, Unsaturated | 4 | 2009 | 34 | 0.180 |
Why?
|
| Prostaglandins F, Synthetic | 2 | 2016 | 6 | 0.180 |
Why?
|
| Thioctic Acid | 2 | 2016 | 14 | 0.180 |
Why?
|
| Lens, Crystalline | 1 | 2019 | 14 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2015 | 396 | 0.170 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 274 | 0.170 |
Why?
|
| Intracellular Fluid | 1 | 1998 | 26 | 0.170 |
Why?
|
| Chromaffin Cells | 1 | 2018 | 4 | 0.170 |
Why?
|
| Ophthalmic Artery | 1 | 2018 | 3 | 0.160 |
Why?
|
| Exocytosis | 1 | 2018 | 45 | 0.160 |
Why?
|
| Excitatory Amino Acids | 1 | 2017 | 7 | 0.160 |
Why?
|
| Humans | 21 | 2021 | 34853 | 0.160 |
Why?
|
| Anti-Obesity Agents | 2 | 2009 | 7 | 0.150 |
Why?
|
| Anterior Eye Segment | 1 | 2017 | 12 | 0.150 |
Why?
|
| Cells, Cultured | 4 | 2018 | 1442 | 0.150 |
Why?
|
| Xanthones | 2 | 2009 | 2 | 0.150 |
Why?
|
| Cholinergic Agonists | 2 | 2010 | 7 | 0.140 |
Why?
|
| Garcinia cambogia | 3 | 2004 | 3 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 1998 | 416 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2009 | 30 | 0.140 |
Why?
|
| Dopamine | 2 | 1995 | 232 | 0.140 |
Why?
|
| Potassium | 3 | 2018 | 110 | 0.140 |
Why?
|
| Neuropeptide Y | 2 | 1999 | 23 | 0.140 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 2 | 2009 | 6 | 0.140 |
Why?
|
| Liver | 3 | 2009 | 447 | 0.140 |
Why?
|
| Software Design | 1 | 2015 | 15 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 231 | 0.130 |
Why?
|
| Albuterol | 3 | 1991 | 9 | 0.130 |
Why?
|
| Receptors, Angiotensin | 2 | 1993 | 11 | 0.130 |
Why?
|
| Rod Cell Outer Segment | 1 | 1994 | 8 | 0.130 |
Why?
|
| Second Messenger Systems | 1 | 1993 | 14 | 0.120 |
Why?
|
| DNA Fragmentation | 2 | 2004 | 91 | 0.120 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2008 | 3 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 57 | 0.120 |
Why?
|
| Plant Extracts | 4 | 2004 | 250 | 0.120 |
Why?
|
| Male | 18 | 2016 | 18870 | 0.110 |
Why?
|
| Angiotensin II | 1 | 1993 | 92 | 0.110 |
Why?
|
| Esophagus | 2 | 1992 | 41 | 0.110 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 2 | 2006 | 38 | 0.110 |
Why?
|
| Aminooxyacetic Acid | 1 | 2012 | 3 | 0.110 |
Why?
|
| Estrus | 2 | 1989 | 14 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2023 | 406 | 0.100 |
Why?
|
| Perfusion | 2 | 2003 | 31 | 0.100 |
Why?
|
| Nitrendipine | 2 | 2003 | 2 | 0.100 |
Why?
|
| Aged | 7 | 2001 | 6448 | 0.100 |
Why?
|
| Female | 17 | 2004 | 19873 | 0.100 |
Why?
|
| Sympathomimetics | 1 | 1991 | 8 | 0.100 |
Why?
|
| Adult | 10 | 2001 | 11034 | 0.100 |
Why?
|
| Pregnancy, Animal | 1 | 1991 | 16 | 0.100 |
Why?
|
| Benzeneacetamides | 1 | 1990 | 4 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2012 | 423 | 0.100 |
Why?
|
| Weight Loss | 2 | 2009 | 124 | 0.100 |
Why?
|
| Glyburide | 1 | 2010 | 8 | 0.090 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2009 | 13 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2009 | 196 | 0.090 |
Why?
|
| Glutamine | 1 | 2009 | 31 | 0.090 |
Why?
|
| Superoxide Dismutase | 2 | 2021 | 149 | 0.090 |
Why?
|
| Hydrogen | 2 | 2021 | 47 | 0.090 |
Why?
|
| Middle Aged | 8 | 2001 | 9642 | 0.090 |
Why?
|
| Glutathione | 2 | 2021 | 160 | 0.090 |
Why?
|
| Aging | 1 | 1994 | 639 | 0.090 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 132 | 0.090 |
Why?
|
| Naloxone | 1 | 1989 | 50 | 0.090 |
Why?
|
| Narcotics | 1 | 1989 | 28 | 0.090 |
Why?
|
| Miotics | 1 | 2008 | 2 | 0.090 |
Why?
|
| Sus scrofa | 1 | 2008 | 21 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1988 | 27 | 0.080 |
Why?
|
| Obesity | 2 | 2007 | 965 | 0.080 |
Why?
|
| Biguanides | 2 | 2003 | 7 | 0.080 |
Why?
|
| Histamine Agonists | 1 | 2006 | 1 | 0.070 |
Why?
|
| Receptors, Histamine | 1 | 2006 | 3 | 0.070 |
Why?
|
| Histamine Antagonists | 1 | 2006 | 6 | 0.070 |
Why?
|
| Lipids | 2 | 2004 | 222 | 0.070 |
Why?
|
| Ocular Hypotension | 1 | 2005 | 3 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2007 | 177 | 0.070 |
Why?
|
| Yohimbine | 2 | 1998 | 26 | 0.070 |
Why?
|
| Melatonin | 2 | 1997 | 78 | 0.060 |
Why?
|
| Calcium Channels | 2 | 2018 | 72 | 0.060 |
Why?
|
| Food Additives | 1 | 2004 | 3 | 0.060 |
Why?
|
| Clonidine | 2 | 1998 | 47 | 0.060 |
Why?
|
| Appetite Depressants | 1 | 2004 | 8 | 0.060 |
Why?
|
| Mitochondria | 2 | 2018 | 454 | 0.060 |
Why?
|
| Diltiazem | 1 | 2003 | 3 | 0.060 |
Why?
|
| Verapamil | 1 | 2003 | 6 | 0.060 |
Why?
|
| omega-Conotoxins | 1 | 2003 | 4 | 0.060 |
Why?
|
| Kainic Acid | 1 | 2003 | 47 | 0.060 |
Why?
|
| Receptors, Glutamate | 1 | 2003 | 26 | 0.060 |
Why?
|
| Dizocilpine Maleate | 1 | 2003 | 45 | 0.060 |
Why?
|
| N-Methylaspartate | 1 | 2003 | 55 | 0.060 |
Why?
|
| Polyamines | 1 | 2003 | 28 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2004 | 62 | 0.060 |
Why?
|
| Cyclic GMP | 2 | 1993 | 44 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 140 | 0.060 |
Why?
|
| Inflammation | 1 | 2007 | 577 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 445 | 0.050 |
Why?
|
| Testis | 1 | 2003 | 185 | 0.050 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2000 | 11 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 173 | 0.050 |
Why?
|
| Thromboxane-A Synthase | 1 | 2001 | 1 | 0.050 |
Why?
|
| Isomerism | 1 | 2001 | 62 | 0.050 |
Why?
|
| Peptides | 2 | 1998 | 308 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2001 | 40 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1300 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2001 | 55 | 0.050 |
Why?
|
| Amitrole | 1 | 2000 | 4 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2001 | 54 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 901 | 0.050 |
Why?
|
| Benzene Derivatives | 1 | 2000 | 4 | 0.050 |
Why?
|
| Prostaglandins E | 2 | 1991 | 3 | 0.050 |
Why?
|
| Beclomethasone | 1 | 2000 | 2 | 0.050 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2000 | 26 | 0.050 |
Why?
|
| Oxidants | 1 | 2000 | 43 | 0.050 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2000 | 19 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2000 | 30 | 0.050 |
Why?
|
| Reference Standards | 1 | 2019 | 52 | 0.040 |
Why?
|
| Acetylcholine | 2 | 1991 | 68 | 0.040 |
Why?
|
| Ganglionectomy | 1 | 1999 | 2 | 0.040 |
Why?
|
| Ruthenium Red | 1 | 1998 | 4 | 0.040 |
Why?
|
| Thapsigargin | 1 | 1998 | 6 | 0.040 |
Why?
|
| Oligomycins | 1 | 1998 | 3 | 0.040 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1998 | 11 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1998 | 14 | 0.040 |
Why?
|
| Neuroeffector Junction | 1 | 1998 | 1 | 0.040 |
Why?
|
| Oxymetazoline | 1 | 1998 | 3 | 0.040 |
Why?
|
| Adrenergic Fibers | 1 | 1998 | 3 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1998 | 23 | 0.040 |
Why?
|
| Quinoxalines | 1 | 1998 | 27 | 0.040 |
Why?
|
| Chelating Agents | 1 | 1998 | 53 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 1534 | 0.040 |
Why?
|
| omega-Conotoxin GVIA | 1 | 1998 | 6 | 0.040 |
Why?
|
| Cytosol | 1 | 2018 | 85 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2018 | 63 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2017 | 17 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2000 | 251 | 0.040 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1997 | 1 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 101 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2018 | 95 | 0.040 |
Why?
|
| Homeostasis | 1 | 1998 | 172 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1997 | 65 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 1997 | 228 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 182 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2009 | 75 | 0.040 |
Why?
|
| Antioxidants | 1 | 2019 | 386 | 0.030 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1995 | 16 | 0.030 |
Why?
|
| Cytokines | 1 | 1998 | 569 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 1994 | 15 | 0.030 |
Why?
|
| Membrane Fluidity | 1 | 1994 | 11 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 1994 | 26 | 0.030 |
Why?
|
| Prostaglandin Antagonists | 1 | 1994 | 1 | 0.030 |
Why?
|
| Xanthenes | 1 | 1994 | 11 | 0.030 |
Why?
|
| Apomorphine | 1 | 1994 | 13 | 0.030 |
Why?
|
| Receptors, Melatonin | 1 | 1994 | 11 | 0.030 |
Why?
|
| Saralasin | 1 | 1993 | 1 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 613 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1993 | 19 | 0.030 |
Why?
|
| Phosphatidylinositols | 1 | 1993 | 12 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1994 | 68 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1994 | 135 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1994 | 360 | 0.030 |
Why?
|
| Prostaglandins E, Synthetic | 1 | 1991 | 1 | 0.030 |
Why?
|
| Adolescent | 3 | 1998 | 5035 | 0.030 |
Why?
|
| Sodium Channels | 1 | 1991 | 63 | 0.030 |
Why?
|
| Epinephrine | 1 | 1991 | 35 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 18 | 0.020 |
Why?
|
| Indomethacin | 1 | 1990 | 24 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 1990 | 30 | 0.020 |
Why?
|
| Pancreatic Polypeptide | 1 | 1990 | 2 | 0.020 |
Why?
|
| Peptide YY | 1 | 1990 | 2 | 0.020 |
Why?
|
| Atropine | 1 | 1990 | 12 | 0.020 |
Why?
|
| Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide | 1 | 2009 | 1 | 0.020 |
Why?
|
| Endometrium | 1 | 1991 | 57 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2009 | 18 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 5 | 0.020 |
Why?
|
| Benzofurans | 1 | 2009 | 19 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 52 | 0.020 |
Why?
|
| Phytohemagglutinins | 2 | 2000 | 12 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 137 | 0.020 |
Why?
|
| Enkephalin, Methionine | 1 | 1989 | 7 | 0.020 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1989 | 17 | 0.020 |
Why?
|
| Enkephalins | 1 | 1989 | 31 | 0.020 |
Why?
|
| Time Factors | 2 | 2004 | 1681 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 1993 | 2333 | 0.020 |
Why?
|
| Benzopyrans | 1 | 1988 | 10 | 0.020 |
Why?
|
| Guanidines | 1 | 1988 | 17 | 0.020 |
Why?
|
| Morphine | 1 | 1989 | 80 | 0.020 |
Why?
|
| Pyrroles | 1 | 1988 | 54 | 0.020 |
Why?
|
| Papaverine | 1 | 1988 | 1 | 0.020 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1988 | 6 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 195 | 0.020 |
Why?
|
| Ovariectomy | 1 | 1988 | 104 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2007 | 22 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 109 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 129 | 0.020 |
Why?
|
| Eating | 1 | 2007 | 152 | 0.020 |
Why?
|
| Pregnancy | 1 | 1991 | 1503 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1988 | 284 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1993 | 1802 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 580 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2004 | 6 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2004 | 42 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2004 | 33 | 0.020 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2003 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2004 | 148 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2004 | 65 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2004 | 212 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2004 | 56 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 99 | 0.010 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 233 | 0.010 |
Why?
|
| Tropanes | 1 | 2002 | 6 | 0.010 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Leptin | 1 | 2003 | 115 | 0.010 |
Why?
|
| Fruit | 1 | 2004 | 159 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2004 | 159 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 727 | 0.010 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2000 | 3 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2000 | 56 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2004 | 775 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2001 | 467 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 528 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2000 | 87 | 0.010 |
Why?
|
| Superior Cervical Ganglion | 1 | 1999 | 5 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 222 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 1998 | 9 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 39 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1998 | 69 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1998 | 80 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 112 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 224 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1998 | 325 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 1289 | 0.010 |
Why?
|
| Asthma | 1 | 2000 | 363 | 0.010 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 1993 | 8 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1993 | 11 | 0.010 |
Why?
|
| Cromakalim | 1 | 1988 | 1 | 0.010 |
Why?
|
| Pinacidil | 1 | 1988 | 1 | 0.010 |
Why?
|
| Rubidium Radioisotopes | 1 | 1988 | 2 | 0.010 |
Why?
|
| Tetrodotoxin | 1 | 1988 | 20 | 0.010 |
Why?
|
| Nifedipine | 1 | 1988 | 12 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1988 | 141 | 0.010 |
Why?
|
| Potassium Channels | 1 | 1988 | 73 | 0.010 |
Why?
|
| Child | 1 | 1993 | 2875 | 0.000 |
Why?
|